Company intelligence / Profile preview

AN2 Therapeutics, Inc.

Menlo Park, California, United States

Ownership: Public · ANTX
Employees: ~50
Development stage: Other

Overview

The company's lead candidate epetraborole for treatment-refractory MAC lung disease did not meet its primary endpoint in the Phase 3 portion of the EBO-301 study. The Phase 2 portion had shown nominal statistical significance on two patient-reported outcome measures. The company is now focusing on other pipeline programs including treatments for Chagas disease and melioidosis, as well as developing oncology candidates.

Therapeutic areas: Infectious Diseases
Modalities: Small moleculesboron-based compounds
Industry: Biotech

Drug pipeline

2 assets

epetraborole

1 more asset in the full pipeline.

Request access →

Partnerships

Bill and Melinda Gates FoundationWellcome TrustMedicines for Malaria VentureDrugs for Neglected Disease initiative (DNDi)GlaxoSmithKline (GSK)Eli Lilly & Company

Financials

Market cap: $204.9M
Total revenue: $0
Enterprise value: $126.5M

Beyond the preview

Go deeper on AN2 Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN2 Therapeutics, Inc..

Explore the full profile